1. Indications:

Paribac (Niraparib) 100 mg is indicated for the treatment of:

• Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

2. Pharmacology:

Paribac (Niraparib) 100 mg exerts its pharmacological effects by selectively inhibiting the activity of poly (ADP-ribose) polymerase (PARP) enzymes. By inhibiting PARP, Paribac prevents the repair of DNA damage in cancer cells, leading to the accumulation of DNA lesions and eventual cell death, particularly in cells with defective DNA repair mechanisms, such as those with BRCA mutations.

3. Dosage and Administration:

The recommended dosage of Paribac (Niraparib) 100 mg may vary depending on individual patient characteristics. Typically, the prescribed dose is 100 mg taken orally once daily, with or without food. Treatment should continue until disease progression or unacceptable toxicity occurs. Dose adjustments or discontinuation may be necessary based on individual patient response and tolerability.

4. Interaction:

Paribac (Niraparib) 100 mg may interact with other medications, including:

• Strong CYP3A4 inhibitors or inducers: Co-administration with drugs that affect CYP3A4 metabolism may alter the plasma concentration of Niraparib.
• Acid-reducing agents: Concurrent use of proton pump inhibitors (PPIs) or H2-receptor antagonists may decrease the absorption of Niraparib, potentially reducing its efficacy.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions.

5. Side Effects:

Common side effects associated with Paribac (Niraparib) 100 mg may include:

• Thrombocytopenia (low platelet count)
• Anemia
• Neutropenia (low white blood cell count)
• Nausea
• Fatigue
• Constipation

Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Paribac (Niraparib) 100 mg, patients should be aware of the following precautions:

• Paribac may cause myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Patients should be monitored for hematologic toxicities during treatment.
• Hypertension has been reported with Niraparib. Blood pressure should be monitored regularly during treatment.
• Niraparib may cause fetal harm if used during pregnancy. Female patients of reproductive potential should use effective contraception during treatment and for at least six months after the last dose.

7. Overdose Effects:

In case of overdose with Paribac (Niraparib) 100 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Niraparib overdose, and patients should seek immediate medical attention if overdose is suspected.